Liquid biopsy in H3K27M diffuse midline glioma

Diffuse midline glioma (DMG) with H3K27M mutation is an aggressive and difficult to treat pediatric brain tumor. Recurrent gain of function mutations in H3.3 (H3.3A) and H3.1 (H3C2) at the 27th lysine to methionine (H3K27M) are seen in over 2/3 of DMGs, and are associated with a worse prognosis. Due...

Full description

Saved in:
Bibliographic Details
Published in:Neuro-oncology (Charlottesville, Va.) Va.), 2024-05, Vol.26 (Supplement_2), p.S101-S109
Main Authors: Patel, Jina, Aittaleb, Rayan, Doherty, Robert, Gera, Ananya, Lau, Benison, Messinger, Dana, Wadden, Jack, Franson, Andrea, Saratsis, Amanda, Koschmann, Carl
Format: Article
Language:English
Subjects:
Biomarkers, Tumor - genetics
Brain Neoplasms - diagnosis
Brain Neoplasms - genetics
Brain Neoplasms - pathology
Glioma - diagnosis
Glioma - genetics
Glioma - pathology
Histones - genetics
Humans
Liquid Biopsy - methods
Mutation
Prognosis
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Diffuse midline glioma (DMG) with H3K27M mutation is an aggressive and difficult to treat pediatric brain tumor. Recurrent gain of function mutations in H3.3 (H3.3A) and H3.1 (H3C2) at the 27th lysine to methionine (H3K27M) are seen in over 2/3 of DMGs, and are associated with a worse prognosis. Due to the anatomical location of DMG, traditional biopsy carries risk for neurologic injury as it requires penetration of vital midline structures. Further, radiographic (MRI) monitoring of DMG often shows nonspecific changes, which makes therapeutic monitoring difficult. This indicates a critical need for more minimally invasive methods, such as liquid biopsy, to understand, diagnose, and monitor H3K27M DMG. Here, we review the use of all modalities to date to detect biomarkers of H3K27M in cerebrospinal fluid (CSF), blood, and urine, and compare their effectiveness in detection, diagnosis, and monitoring treatment response. We provide specific detail of recent efforts to monitor CSF and plasma H3K27M cell-free DNA in patients undergoing therapy with the imipridone ONC201. Lastly, we discuss the future of therapeutic monitoring of H3K27M-DMG, including biomarkers such as mitochondrial DNA, mutant and modified histones, and novel sequencing-based approaches for improved detection methods.
ISSN:1522-8517
1523-5866
1523-5866
DOI:10.1093/neuonc/noad229